drugset / Trial / NCT04647487
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery
RandomizedParallel-groupOpen-labelBasic science
Summary
The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.
Timeline
- Start
- 2021-04-21
- Primary completion
- 2022-11-11
- Completion
- 2022-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imlunestrant | Small molecule | 200 mg | Oral |
| Subject | Imlunestrant | Small molecule | 400 mg | Oral |
| Subject | Imlunestrant | Small molecule | 800 mg | Oral |